Gandhi Gunjan Y, Kovalaske Michelle, Kudva Yogish, Walsh Kristin, Elamin Mohamed B, Beers Melody, Coyle Cathy, Goalen Melissa, Murad Mohammad Safwan, Erwin Patricia J, Corpus Joshua, Montori Victor M, Murad M Hassan
Division of Endocrinology, Mayo Clinic, Jacksonville, Florida 32224, USA.
J Diabetes Sci Technol. 2011 Jul 1;5(4):952-65. doi: 10.1177/193229681100500419.
We conducted a systematic review and meta-analysis to assess the efficacy of continuous glucose monitoring (CGM) in improving glycemic control and reducing hypoglycemia compared to self-monitored blood glucose (SMBG).
We searched MEDLINE, EMBASE, Cochrane Central, Web of Science, and Scopus for randomized trials of adults and children with type 1 or type 2 diabetes mellitus (T1DM or T2DM). Pairs of reviewers independently selected studies, assessed methodological quality, and extracted data. Meta-analytic estimates of treatment effects were generated using a random-effects model.
Nineteen trials were eligible and provided data for meta-analysis. Overall, CGM was associated with a significant reduction in mean hemoglobin A1c [HbA1c; weighted mean difference (WMD) of -0.27% (95% confidence interval [CI] -0.44 to -0.10)]. This was true for adults with T1DM as well as T2DM [WMD -0.50% (95% CI -0.69 to -0.30) and -0.70 (95% CI, -1.14 to -0.27), respectively]. No significant effect was noted in children and adolescents. There was no significant difference in HbA1c reduction between studies of real-time versus non-realtime devices (WMD -0.22%, 95% CI, -0.59 to 0.15 versus -0.30%, 95% CI, -0.49 to -0.10; p for interaction 0.71). The quality of evidence was moderate due to imprecision, suggesting increased risk for bias. Data for the incidence of severe or nocturnal hypoglycemia were sparse and imprecise. In studies that reported patient satisfaction, users felt confident about the device and gave positive reviews.
Continuous glucose monitoring seems to help improve glycemic control in adults with T1DM and T2DM. The effect on hypoglycemia incidence is imprecise and unclear. Larger trials with longer follow-up are needed to assess the efficacy of CGM in reducing patient-important complications without significantly increasing the burden of care for patients with diabetes.
我们进行了一项系统评价和荟萃分析,以评估与自我血糖监测(SMBG)相比,持续葡萄糖监测(CGM)在改善血糖控制和降低低血糖方面的疗效。
我们检索了MEDLINE、EMBASE、Cochrane Central、Web of Science和Scopus,以查找1型或2型糖尿病(T1DM或T2DM)成人及儿童的随机试验。由两位评审员独立选择研究、评估方法学质量并提取数据。使用随机效应模型生成治疗效果的荟萃分析估计值。
19项试验符合条件并提供了荟萃分析的数据。总体而言,CGM与平均糖化血红蛋白A1c [HbA1c]的显著降低相关[加权平均差(WMD)为-0.27%(95%置信区间[CI] -0.44至-0.10)]。T1DM和T2DM成人患者均如此[WMD分别为-0.50%(95% CI -0.69至-0.30)和-0.70(95% CI,-1.14至-0.27)]。儿童和青少年中未观察到显著效果。实时与非实时设备的研究在HbA1c降低方面无显著差异(WMD分别为-0.22%[95% CI,-0.59至0.15]和-0.30%[95% CI,-0.49至-0.10];交互作用p值为0.71)。由于不精确性,证据质量为中等,提示存在偏倚风险增加。严重或夜间低血糖发生率的数据稀少且不精确。在报告患者满意度的研究中,使用者对该设备有信心并给予积极评价。
持续葡萄糖监测似乎有助于改善T1DM和T2DM成人患者的血糖控制。对低血糖发生率的影响不精确且不明确。需要进行更大规模、随访时间更长的试验,以评估CGM在不显著增加糖尿病患者护理负担的情况下减少对患者重要并发症的疗效。